Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 7:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Candidiasis, Oral Clear all

Completed Not applicable Interventional

Acidophilus for the Treatment and Prevention of Oral Candidiasis in Patients Undergoing Radiation Therapy

NCT00768794

View directory record Official record

Conditions: Oral Candidiasis
Interventions: Acidophilus, Acidolphilus; Dietary Supplement
Lead sponsor: Summa Health System; Other
Eligibility: 18 Years to 80 Years

Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Akron, Ohio

Source: ClinicalTrials.gov public record

Updated May 30, 2013 · Synced May 21, 2026, 7:45 PM EDT

Completed Not applicable Interventional

The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients

NCT00002431

View directory record Official record

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Chlorhexidine gluconate; Drug
Lead sponsor: Procter and Gamble; Industry
Eligibility: 13 Years to 75 Years

Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Los Angeles, California • San Francisco, California • Columbus, Ohio + 1 more

Source: ClinicalTrials.gov public record

Updated Jun 23, 2005 · Synced May 21, 2026, 7:45 PM EDT

Completed Phase 4 Interventional

A Study to Compare the Use of Fluconazole as Continuous Therapy Versus Periodic Therapy in HIV-Positive Patients With Recurrent Thrush

NCT00000951

View directory record Official record

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Fluconazole; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older

Enrollment: 948 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 53
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 28 more

Source: ClinicalTrials.gov public record

Updated Oct 28, 2021 · Synced May 21, 2026, 7:45 PM EDT

Completed Not applicable Interventional

Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)

NCT00002043

View directory record Official record

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Dapsone; Drug
Lead sponsor: Jacobus Pharmaceutical; Industry
Eligibility: 12 Years and older

Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Los Angeles, California

Source: ClinicalTrials.gov public record

Updated Jun 23, 2005 · Synced May 21, 2026, 7:45 PM EDT

Completed Phase 3 Interventional Results available

Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)

NCT03363841

View directory record Official record

Conditions: Candidiasis, Invasive, Candidemia
Interventions: SCY-078; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Jersey City, New Jersey

Source: ClinicalTrials.gov public record

Updated Jul 2, 2024 · Synced May 21, 2026, 7:45 PM EDT

Completed Phase 3 Interventional

Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients

NCT00002446

View directory record Official record

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Posaconazole, Fluconazole; Drug
Lead sponsor: Schering-Plough; Industry
Eligibility: 18 Years and older

Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 17
States / cities: Berkeley, California • San Francisco, California • Denver, Colorado + 13 more

Source: ClinicalTrials.gov public record

Updated Jun 23, 2005 · Synced May 21, 2026, 7:45 PM EDT

Completed Not applicable Interventional

A Comparison of the Safety and Effectiveness of Fluconazole or Clotrimazole in the Treatment of Fungal Infections of the Mouth and Throat in Patients With AIDS

NCT00002282

View directory record Official record

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Clotrimazole, Fluconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years and older

Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 17
States / cities: Los Angeles, California • Oakland, California • San Francisco, California + 12 more

Source: ClinicalTrials.gov public record

Updated Jun 23, 2005 · Synced May 21, 2026, 7:45 PM EDT

Completed Phase 2 Interventional

A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients

NCT00002399

View directory record Official record

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Posaconazole, Fluconazole; Drug
Lead sponsor: Schering-Plough; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 17
States / cities: Tucson, Arizona • Jonesboro, Arkansas • Miami, Florida + 13 more

Source: ClinicalTrials.gov public record

Updated Jun 23, 2005 · Synced May 21, 2026, 7:45 PM EDT

Terminated No phase listed Observational

Incidence of Oral Candidiasis, Prevalence of C. Dubliniensis in HIV Patients and In-vitro Azole Susceptibility

NCT00692783

View directory record Official record

Conditions: Candidiasis, HIV Infections
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years

Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Jacksonville, Florida

Source: ClinicalTrials.gov public record

Updated May 7, 2015 · Synced May 21, 2026, 7:45 PM EDT

Completed Phase 3 Interventional

A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2

NCT00001812

View directory record Official record

Conditions: Candidiasis, Oral, Gastrointestinal Diseases, Stomatitis
Interventions: Nystatin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed

Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Source: ClinicalTrials.gov public record

Updated Mar 3, 2008 · Synced May 21, 2026, 7:45 PM EDT

Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)

NCT01891331

View directory record Official record

Conditions: Candidiasis, Vulvovaginal
Interventions: VT-1161, Fluconazole; Drug
Lead sponsor: Viamet; Industry
Eligibility: 18 Years to 65 Years · Female only

Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 8
States / cities: Lake Worth, Florida • North Miami, Florida • Brooklyn, New York + 5 more

Source: ClinicalTrials.gov public record

Updated Jul 31, 2018 · Synced May 21, 2026, 7:45 PM EDT

Completed Not applicable Interventional

Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment

NCT00002394

View directory record Official record

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Terbinafine hydrochloride; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older

Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: Fort Lauderdale, Florida • Fort Myers, Florida • Tamarac, Florida + 6 more

Source: ClinicalTrials.gov public record

Updated Jun 23, 2005 · Synced May 21, 2026, 7:45 PM EDT

Completed Not applicable Interventional

Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome

NCT00002112

View directory record Official record

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Nystatin, Fluconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years and older

Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Fresno, California • San Francisco, California • Baltimore, Maryland + 2 more

Source: ClinicalTrials.gov public record

Updated Jun 23, 2005 · Synced May 21, 2026, 7:45 PM EDT

Completed Phase 2 Interventional Results available

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

NCT02734862

View directory record Official record

Conditions: Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis
Interventions: CD101, Caspofungin, Fluconazole, intravenous placebo, oral placebo; Drug
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older

Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 16
States / cities: Birmingham, Alabama • Davis, California • Miami, Florida + 12 more

Source: ClinicalTrials.gov public record

Updated Dec 7, 2020 · Synced May 21, 2026, 7:45 PM EDT

Completed Not applicable Interventional

A Study of Treatments for Fungal Infections of the Mouth and Throat in HIV-Infected Patients Who Have Had Success With Itraconazole But Not With Fluconazole

NCT00002341

View directory record Official record

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Itraconazole; Drug
Lead sponsor: Janssen, LP; Industry
Eligibility: 18 Years to 65 Years

Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Source: ClinicalTrials.gov public record

Updated Jun 23, 2005 · Synced May 21, 2026, 7:45 PM EDT

Completed Phase 2 Interventional Results available

A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

NCT02267382

View directory record Official record

Conditions: Recurrent Vulvovaginal Candidiasis
Interventions: VT-1161, Placebo; Drug
Lead sponsor: Viamet; Industry
Eligibility: 18 Years to 65 Years · Female only

Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 32
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 27 more

Source: ClinicalTrials.gov public record

Updated Oct 14, 2019 · Synced May 21, 2026, 7:45 PM EDT

Terminated Phase 2 Interventional

Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole

NCT00005920

View directory record Official record

Conditions: Candidiasis, Oral, HIV Infections
Interventions: L-743,872; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Rahway, New Jersey

Source: ClinicalTrials.gov public record

Updated Jun 23, 2005 · Synced May 21, 2026, 7:45 PM EDT

Completed Not applicable Interventional

An Open Study of the Effect of Itraconazole Oral Solution for the Treatment of Fluconazole Refractory Oropharyngeal Candidiasis in HIV-Positive Subjects.

NCT00002133

View directory record Official record

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Itraconazole; Drug
Lead sponsor: Janssen, LP; Industry
Eligibility: 18 Years to 65 Years

Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 18
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Berkeley, California + 13 more

Source: ClinicalTrials.gov public record

Updated Jun 23, 2005 · Synced May 21, 2026, 7:45 PM EDT

Completed Phase 3 Interventional Results available

Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections

NCT03840616

View directory record Official record

Conditions: Recurrent Vulvovaginal Candidiasis
Interventions: Oteseconazole (VT-1161) 150mg capsule, Fluconazole 150mg capsule, Placebo; Drug
Lead sponsor: Mycovia Pharmaceuticals Inc.; Industry
Eligibility: 12 Years and older · Female only

Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 33
States / cities: Tucson, Arizona • Encino, California • Los Angeles, California + 30 more

Source: ClinicalTrials.gov public record

Updated Feb 3, 2022 · Synced May 21, 2026, 7:45 PM EDT

Completed Phase 3 Interventional Results available

A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

NCT03562156

View directory record Official record

Conditions: Recurrent Vulvovaginal Candidiasis
Interventions: Oteseconazole (VT-1161), Placebo; Drug
Lead sponsor: Mycovia Pharmaceuticals Inc.; Industry
Eligibility: 12 Years and older · Female only

Enrollment: 438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 25
States / cities: Birmingham, Alabama • San Diego, California • Lauderdale Lakes, Florida + 21 more

Source: ClinicalTrials.gov public record

Updated Feb 16, 2026 · Synced May 21, 2026, 7:45 PM EDT

Completed Phase 2 Interventional Results available

Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)

NCT02971007

View directory record Official record

Conditions: Vulvovaginitis, Yeast Infection, Yeast Infection Vaginal, Candidiasis, Vulvovaginal
Interventions: Oral Encochleated Amphotericin B (CAMB), Fluconazole; Drug
Lead sponsor: Matinas BioPharma Nanotechnologies, Inc.; Industry
Eligibility: 18 Years to 65 Years · Female only

Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more

Source: ClinicalTrials.gov public record

Updated Nov 1, 2018 · Synced May 21, 2026, 7:45 PM EDT

Completed Phase 3 Interventional Results available

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

NCT03667690

View directory record Official record

Conditions: Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
Interventions: Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo; Drug
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older

Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 19
States / cities: Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more

Source: ClinicalTrials.gov public record

Updated Jan 5, 2023 · Synced May 21, 2026, 7:45 PM EDT

Completed Not applicable Interventional

Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients

NCT00002041

View directory record Official record

Conditions: Candidiasis, Esophageal, HIV Infections
Interventions: Amphotericin B; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 16 Years and older

Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Princeton, New Jersey

Source: ClinicalTrials.gov public record

Updated Oct 1, 2007 · Synced May 21, 2026, 7:45 PM EDT

Completed Phase 3 Interventional Results available

A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

NCT03561701

View directory record Official record

Conditions: Recurrent Vulvovaginal Candidiasis
Interventions: Oteseconazole (VT-1161), Placebo; Drug
Lead sponsor: Mycovia Pharmaceuticals Inc.; Industry
Eligibility: 12 Years and older · Female only

Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 14
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more

Source: ClinicalTrials.gov public record

Updated Feb 16, 2026 · Synced May 21, 2026, 7:45 PM EDT